Page 363 - Multidisipliner Covid 19

COVID-19 Pandemisinde Nörolojik Hastal›klar

32. Fishman PS, Gass JS, Swoveland PT, Lavi E, Highkin MK, Weiss SR.
Infection of the basal ganglia by a murine coronavirus. Science. 1985;
229(4716):877-879.
33. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to corona-
virus in patients with Parkinson’s disease. Mov Disord. 1992;7(2):
153–158.
34. Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic
on Parkinson’s disease and movement disorders. Mov Disord. 2020;-
35(5):711-715.
35. Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. COVID-19:
An Early Review of Its Global Impact and Considerations for Parkinson’s
Disease Patient Care. J Mov Disord. 2020;13(2):105-114.
36. French JA, Brodie MJ, Caraballo R, et al. Keeping people with epilepsy
safe during the Covid-19 pandemic. Neurology. 2020; 94(23):1032-1037.
37. Coles A and the MS Advisory Group, in consultation with: Lim M on
behalf of paediatric MS group, Giovannoni G on behalf of MS Academy,
Anderson P for the MS Society, Dorsey-Campbell R for MS pharmacists,
Qualie M for NHS England. Association of British Neurologists (ABN)
guidance on the use of disease-modifying therapies in multiple sclerosis
in response to the threat of a coronavirus epidemic. https://cdn.ymaws.
com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-
93AA74B3A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_
and_COVID19_ VERSION_4_April_2nd.pdf
38. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold
J. The COVID-19 pandemic and the use of MS disease-modifying ther-
apies. Mult Scler Relat Disord. 2020;39:102073.
39. Foerch C, Friedauer L, Bauer B, et al. Severe COVID-19 infection in a
patient with multiple sclerosis treated with fingolimod. Mult Scler
Relat Disord.2020;42:102180.
40. Matias-Guiu J, Montero-Escribano P, Pytel V, Porta-Etessam J, Matias-
Guiu JA. Potential COVID-19 infection in patients with severe multiple
sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2020;44:
102297
41. Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors
associated with acute exacerbations of myasthenia gravis. Muscle
Nerve. 2019;60(6):693-699.
42. International MG/COVID-19 Working Group: Jacob S, Muppidi S,

362